Abiopharma

🔍 Schwenger Thomas D. (Executive)

Company: VEEVA SYSTEMS INC (VEEV)

Report Date: 2026-04-01

Detailed Transactions and Holdings:

• Acquired 2,043 shares of Class A Common Stock (Direct)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | shares_owned_after: 24,247.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 588 shares of Class A Common Stock at $172.74 per share (Direct)
  Date: 2026-04-01 | Code: F | equity_swap_involved: 0 | shares_owned_after: 23,659.00 | transaction_form_type: 4 | Footnotes: F3, F3
• Sold 2,043 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-01 | Code: M | equity_swap_involved: 0 | transaction_form_type: 4 | Footnotes: F2, F1, F4, F4

Footnotes:

• F1: Transaction exempt from Section 16(b) of the Securities Exchange Act of 1934 (the "Act") pursuant to Rule 16b-6(b) promulgated under the Act.
• F2: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Class A Common Stock of the Issuer.
• F3: Represents shares that have been withheld by the Issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of vested restricted stock units and not a market transaction. Transaction exempt from Section 16(b) of the Act pursuant to Rule 16b-3(e) promulgated under the Act.
• F4: The RSUs were granted under the Issuer's Amended & Restated 2013 Equity Incentive Plan. The Reporting Person vests ownership in the RSUs over one year with 25% vesting on July 1, 2025, and 25% of the RSUs vesting on a quarterly basis thereafter, subject to continued service to the Issuer by the Reporting Person.